ArticleInternational immunology2026
Selective decreases in regulatory B-cell (Breg) subsets in active uveitis: IL-10+CD19+CD24hiCD38hiBregs in patients and B10 Bregs in mice.
Article in International immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Several regulatory B-cell (Breg) subsets have been implicated in autoimmune diseases. We investigated Breg subsets in non-infectious uveitis (NIU) and in mouse models of experimental autoimmune uveitis (EAU). Blood samples from NIU patients with active disease (n = 13), in remission (n = 37) and healthy controls (n = 10) were immunophenotyped for CD19+CD24hiCD38lo memory B cells, CD19+CD24hiCD38hi-immature Bregs (iBregs), and CD19+CD38intCD24int-mature Bregs. In NIU, levels of peripheral blood iBregs and serum interleukin-10 (IL-10) were decreased in active disease vs. remission (P < .01). In quiescent NIU, iBregs were isolated and, when added at increasing ratios to autologous CD3+ T cells, downregulated T-cell proliferation. In an EAU model, at peak disease, CD19+CD1dhiCD5+ B10, CD19+CD5+ B1, CD19+CD21hiCD24hiCD23+ transitional two marginal-zone precursor (T2-MZP) and CD19+CD21hiCD23- marginal-zone B (MZB) Breg subsets were analysed both phenotypically and functionally. In EAU spleens, all Breg subsets investigated were detectable, but the IL-10-expressing B10-Breg subset was immunosuppressive and inversely correlated with disease severity (P = .048, R2 = 0.47). Blood-derived IL-10-expressing B10 and B1 Bregs were increased in both adjuvant controls and EAU but were significantly reduced in clinically milder EAU. In dissociated retinal cells, only the B10-Breg subset was detectable and increased in EAU. Selective Breg subsets may be immunosuppressive, with iBregs in NIU and IL-10-expressing B10 Bregs in EAU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.